Company profile: Novo Nordisk
1.1 - Company Overview
Company description
- Provider of insulin and other diabetes drugs for chronic diseases, GLP-1 treatments for type 2 diabetes, obesity care pharmaceuticals, Mim8 for haemophilia A (weekly or monthly dosing), and ReMed, a recycling program for used injection pens, with a focus on pioneering scientific breakthroughs and expanding access to medicines to prevent and cure disease.
Products and services
- Obesity Care: Pharmaceutical-grade products that assist weight management and reduce obesity-related health risks, supporting the company’s goal of preventing and curing disease
- GLP-1 Diabetes Treatments: Incretin-mimetic class medications engineered to manage blood sugar in type 2 diabetes by mimicking hormones that stimulate insulin release
- Mim8: Indication-specific therapy for haemophilia A that reduces bleeding episodes, administered weekly or monthly to maintain control
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novo Nordisk
DJS Antibodies
HQ: United Kingdom
Website
- Description: Provider of antibody therapeutics and discovery technology targeting GPCRs to treat chronic inflammatory and fibrotic diseases. Offers HEPTAD, a proprietary platform to discover functional, first-in-class antibodies for complex protein targets; DJS 001, a first-in-class program for myeloid cell driven inflammatory disease; and DJS 002, a monoclonal antibody for fibrotic diseases without off-target side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DJS Antibodies company profile →
Pfizer
HQ: United States
Website
- Description: Provider of biopharmaceutical medicines and health care services, delivering affordable access to safe, effective treatments, including vaccines for infectious diseases (COVID-19, pneumonia, meningitis), oncology therapies, cardiovascular medicines for hypertension and cholesterol, anti-infectives (antibiotics, antivirals), treatments for inflammation and immunology, and therapies for rare genetic disorders addressing unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pfizer company profile →
Valera Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical services concentrating on development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valera Pharmaceuticals company profile →
The Medicines Company
HQ: United States
Website
- Description: Provider of innovative, cost-effective medicines to the worldwide hospital marketplace, focused on advancing treatment of critical care patients. Markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full The Medicines Company company profile →
Sagimet Biosciences
HQ: United States
Website
- Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sagimet Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novo Nordisk
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novo Nordisk
2.2 - Growth funds investing in similar companies to Novo Nordisk
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novo Nordisk
4.2 - Public trading comparable groups for Novo Nordisk
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →